So given the context, it would appear that the case could have been dealt with procedurally with all parties -regulators, blood product supplier, hospitals and treatment facilities and agents -being on the same page. The risk from the blood product should have been seen in a universal way by all parties involved in this particular case. But was it? If there are different levels of decisionmaking and risk assumptions do expert assessments necessarily converge? The answer, to anticipate, is yes and no.